- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Tecan Group
Market Cap: CHF 1.6b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 127.80
7D
-8.6%
1Y
-13.9%
Novartis
Market Cap: CHF 221.9b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 116.28
7D
-1.0%
1Y
26.4%
Roche Holding
Market Cap: CHF 259.4b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 324.90
7D
3.6%
1Y
23.9%
Siegfried Holding
Market Cap: CHF 3.5b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 79.15
7D
-3.6%
1Y
-12.8%